华仁药业公告，公司及全资子公司广西裕源药业有限公司、华仁药业（日照）有限公司近期积极参与了 京津冀"3+N"联盟部分西药和中成药带量联动接续采购（项目编号：LH-YD2025-1）的投标工作。根据 天津市医药采购中心近日公布的中选结果，公司及全资子公司产品混合糖电解质注射液、盐酸倍他司汀 氯化钠注射液及羟乙基淀粉130/0.4氯化钠注射液中选本次带量联动接续采购。 ...

华仁药业公告，公司及全资子公司广西裕源药业有限公司、华仁药业（日照）有限公司近期积极参与了 京津冀"3+N"联盟部分西药和中成药带量联动接续采购（项目编号：LH-YD2025-1）的投标工作。根据 天津市医药采购中心近日公布的中选结果，公司及全资子公司产品混合糖电解质注射液、盐酸倍他司汀 氯化钠注射液及羟乙基淀粉130/0.4氯化钠注射液中选本次带量联动接续采购 ...

Group 1 - On September 24, Huaren Pharmaceutical's stock rose by 1.88%, with a trading volume of 58.77 million yuan [1] - The financing data on the same day showed a financing purchase amount of 7.48 million yuan, a repayment of 6.17 million yuan, resulting in a net financing purchase of 1.31 million yuan [1] - As of September 24, the total balance of margin trading for Huaren Pharmaceutical was 261 million yuan, accounting for 6.79% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - As of September 20, the number of shareholders for Huaren Pharmaceutical was 40,500, a decrease of 1.46% from the previous period [2] - The average circulating shares per person increased by 1.48% to 29,156 shares [2] - For the first half of 2025, Huaren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2] Group 3 - Since its A-share listing, Huaren Pharmaceutical has distributed a total of 294 million yuan in dividends [3] - In the last three years, the cumulative dividend payout amounted to 49.65 million yuan [3]

证券代码：300110 证券简称：华仁药业 公告编号：2025-060 华仁药业股份有限公司 关于持股 5%以上股东持股比例变动至 5%以下暨权益变动 的提示性公告 股东红塔创新投资股份有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。本公司及董事会全体成员保证 公告内容与信息披露义务人提供的信息一致。 一、本次权益变动情况 红塔创新为公司首发前股东，本次权益变动前（2010年8月25日，即公司首 次公开发行股份上市时），红塔创新持有公司股份22,260,610股，占当时公司总 股本的比例为10.42%。在2010年8月25日-2025年9月8日期间，红塔创新因减持及 公司股权激励、回购股份、配股累计持股比例减少5.42%。截至本公告披露日， 红塔创新持有公司股份59,110,640股，占公司总股本的比例为4.999999%，不再 是公司持股5%以上的股东。具体情况如下： | 变动日期 | 变动方式 | 变动数量 | 变动比例 | 备注 | | --- | --- | --- | --- | --- | | | | （股） | （%） | | | 2012.02.29 ...

华仁药业股份有限公司 简式权益变动报告书 上市公司名称：华仁药业股份有限公司 股票简称：华仁药业 股票代码：300110 股票上市地点：深圳证券交易所 信息披露义务人：红塔创新投资股份有限公司 住所/通讯地址：云南省昆明市五华区昆明高新区海源北路与科新路交叉口海 源高新天地商业广场1幢21层2108号 权益变动性质：股份减少，持股比例降至5%以下 签署日期：2025年9月9日 1 信息披露义务人声明 一、本报告书系依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第15 号——权益变动报告书》及其他相关法律法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报 告书已全面披露信息披露义务人在华仁药业股份有限公司中拥有权益的股份变动 情况。截至本报告书签署日，除本报告书披露的持股信息外，信息披露义务人没 有通 ...

Group 1 - Huazhong Securities has been approved to issue subordinate corporate bonds with a total face value of no more than 10 billion yuan [1] - Jinbei Automotive plans to invest 240 million yuan to establish an automotive industry investment fund focusing on electrification, intelligence, and low carbon [1] - Linyang Energy is expected to win a bid for a 244 million yuan metering equipment project from Southern Power Grid [1][2] Group 2 - Renfu Pharmaceutical's subsidiary has received drug registration certificates for two products, including a medication for acute hypotension [3][4] - Nanjing Steel plans to distribute a cash dividend of 0.1186 yuan per share [5][6] - Pairui Co. has signed a strategic cooperation agreement with Xi'an Power Electronics Research Institute to develop power devices [7][8] Group 3 - Haixing Electric is expected to win a bid for a 214 million yuan metering equipment project from Southern Power Grid [9][10] - Kuangda Technology is planning a change in control, leading to a continued suspension of its stock [11][12] - Samsung Medical is expected to win a bid for a 274 million yuan metering equipment project from Southern Power Grid [13][14] Group 4 - Jiukang Bio has obtained a medical device registration certificate for a specific diagnostic kit [15][16] - Hechuan Technology's minority shareholder plans to transfer a 13% stake in a subsidiary [17][18] - DiAo Micro has launched a new eUSB2 repeater product for various electronic applications [19][20] Group 5 - David Medical's electric surgical table registration application has been accepted [21][22] - Hangxin Technology plans to apply for a total of 280 million yuan in bank credit [23][24] - Liyuan Technology's non-independent director has resigned [25][26] Group 6 - Ningbo Construction's subsidiary has won a construction project bid worth 729 million yuan [27][28] - Huaren Pharmaceutical's subsidiary has received approval for a raw material drug [29][30] - Suwen Electric plans to distribute a cash dividend of 1 yuan per 10 shares [31][32] Group 7 - Solar Energy has received 1.692 billion yuan in renewable energy subsidies [33][34] - Wangli Security has obtained a patent for a new lock structure [35][36] - Zhejiang Energy's vice chairman has resigned due to age reasons [37][38] Group 8 - Beilu Pharmaceutical's subsidiary has passed GMP certification in Brazil [39][40] - Zhejiang Communications has a subsidiary that is expected to win a highway project bid [41][42] - Xinzhi Group has received a government subsidy of 11.1978 million yuan [43][44] Group 9 - Dong'an Power's engine sales in August increased by 3.44% year-on-year [45][46] - Baiyun Mountain's subsidiary has passed the consistency evaluation for two generic drugs [47][48] - Yipin Hong's subsidiary has received a drug registration certificate for a specific injection [49][50] Group 10 - Far East Holdings' subsidiary has won multiple contracts totaling 1.689 billion yuan [51][52] - Good Housekeeping's shareholder plans to reduce holdings by up to 3.5 million shares [53][54] - Guanghong Technology's shareholders have set a transfer price of 23.33 yuan per share [55][56] Group 11 - Keli Sensor plans to acquire 45% of Huahong Technology's shares for 122 million yuan [57][58] - Jianmin Group's furosemide oral solution has been approved for market launch [59][60] - Jinghua Laser's directors plan to reduce their holdings by up to 143,420 shares [61][62] Group 12 - Zhuyue Group is planning a share transfer that will change its controlling shareholder [63][64] - Terid has pre-bid for two projects totaling approximately 698 million yuan [65][66] - Zhonghuan Hailu is planning a change in control, leading to a continued suspension of its stock and convertible bonds [67][68] Group 13 - Great Wall Motors reported August sales of 115,600 vehicles, a year-on-year increase of 22.33% [69][70] - Guizhou Tire's controlling shareholder has committed not to reduce holdings for 12 months [71][72] - San Da Membrane's shareholder plans to reduce holdings by up to 1% of the company's shares [73][74] Group 14 - Chint Electric has decided to terminate the spin-off of its subsidiary for listing [75][76] - Jusaylong's shareholder plans to reduce holdings by up to 1% of the company's shares [77][78]

Group 1 - The core point of the article is that Huaren Pharmaceutical announced the approval of its subsidiary Anhui Hengxing Pharmaceutical's application for "Isoproterenol Hydrochloride" as a chemical raw material drug by the National Medical Products Administration [1] Group 2 - The approval signifies a significant milestone for the company, potentially enhancing its product portfolio and market competitiveness [1]

Core Viewpoint - Huaren Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of Isoproterenol Hydrochloride, indicating a significant advancement in its product portfolio and potential market opportunities [1] Group 1: Company Developments - Huaren Pharmaceutical's wholly-owned subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd., has been granted the approval for Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist [1] - The approval notification number for the marketing application is 2025YS00767, highlighting the regulatory progress made by the company [1] Group 2: Product Information - Isoproterenol Hydrochloride is known for its strong positive inotropic and chronotropic effects, as well as its bronchodilator properties, making it clinically relevant for treating conditions such as cardiogenic or septic shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1]

Core Viewpoint - Huanren Pharmaceutical's wholly-owned subsidiary, Anhui Hengxing Pharmaceutical, has received approval from the National Medical Products Administration for the production and sale of "Isoproterenol Hydrochloride" in the domestic market [1] Group 1 - The approval includes the issuance of a "Chemical Raw Material Drug Listing Application Approval Notice" [1] - The raw material drug has met the relevant technical standards for raw material drug review in the country [1] - This development allows the company to expand its product offerings in the domestic market [1]

Core Viewpoint - Hainan Pharmaceutical's subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of "Isoproterenol Hydrochloride" [1] Company Summary - The approval of Isoproterenol Hydrochloride, a non-selective β-adrenergic agonist, will enhance the company's active pharmaceutical ingredient (API) product line [1] - This product is primarily used for treating cardiogenic or infectious shock, complete atrioventricular block, cardiac arrest, and acute bronchial asthma attacks [1] - The addition of this product is expected to improve the company's market competitiveness [1]